The market for drugs used for hospital-treated infections such as MRSA will increase to over $4bn by 2020, according to forecasts produced by Decision Resources.

Although there is increased competition and regulatory measures in a number of markets, including the US, sales of drugs used to combat infections are expected to grow from the $3.3bn figure recorded in 2010.

Growth is expected to be constrained by generic erosion, with Pfizer’s Zyvox at particular risk, but new therapy launches will offset losses and account for up to 30% of sales in major markets by 2020.

Analysis and data provider Decision Resources has highlighted Teflaro, co-produced by AstraZeneca, Dainippon Sumitomo and Forest, as the drug best situated for commercial success given its early entry into the market.